Professor Peter Naredi, the
ECCO scientific co-chair of the Congress, who was not involved in the research, commented: «
Although the CheckMate 067 study has already reported that a combination of two checkpoint inhibitors, nivolumab and ipilimumab, is superior to either drug alone, the results presented here in Vienna have important clinical implications.